(Q24244773)

Cochrane Database of Systematic Reviews

inferred from title

cognitive dysfunction

1 reference

Clement Loy

1

0 references

Lon Schneider

series ordinal

2

0 references

publication date

25 January 2006

0 references

published in

0 references

cites work

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Galantamine in the treatment of vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Long-term outcomes of galantamine treatment in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Use of galantamine to treat vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Galanthamine in Alzheimer's disease : a new alternative to tacrine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

The effects of galantamine treatment on caregiver time in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Galantamine: a review of its use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

The pharmacology of galanthamine and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

P2-158 Effect of galantamine treatment on brain atrophy as assessed by MRI in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

7 January 2021

Galantamine hydrobromide: an agent for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001747.PUB3

7 January 2021

10.1002/14651858.CD001747.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

4050167

4050167

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference